Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLM-102
- Development stage
- Unknown
- Lead developer
- TLM
01
Overview
TLM-102 is an investigational Therillume pipeline drug being developed for **Neurofibromatosis Type 1**. Publicly available information identified from the company pipeline indicates that it is a **Phase 1** program for NF1, but the specific active substance, molecular target, modality, route, and mechanism of action have not been publicly disclosed in the source material reviewed. Therillume is described as a division of Recombinetics, and TLM-102 appears to be one of the company's named NF1 development candidates.
Beyond the preview
Go deeper on TLM-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLM-102.